Arrowhead Pharmaceuticals Inc. Insider Trading

ARWR

Last 12 months

Insiders sold $37.3M and bought nothing on the open market.

45% of the selling was scheduled in advance under 10b5-1 plans. Chief Executive Officer Christopher Richard Anzalone sold $12.3M on Dec 16, 2025 outside a plan. The last open-market buy by an executive or director was in Mar 2024.

Net open-market

−$37.3M

0 buys · 19 sales

Under a 10b5-1 plan

45%

of the value sold

Insiders who bought / sold

0 / 10

executives and directors

Last open-market buy

Mar 2024

Mar 20, 2024

Get an email when ARWR's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Aug 18	Michael S Perry Director	SoldNo plan	11,600	$87.30	$1.01M	9.4%	Form 4
Aug 18	Adeoye Y Olukotun Director	SoldNo plan	2,000	$86.96	174K	6.0%	Form 4
May 12	Hongbo Lu Director	Sold10b5-1 plan	2,970	$76.88	228K	5.4%	Form 4
Apr 23	James C Hamilton Chief Medical Officer	Sold10b5-1 plan	10,000	$75.00	750K	4.2%	Form 4
Apr 22	Daniel Joseph Apel Chief Financial Officer	Sold10b5-1 plan 3 parts	13,095	$71.35 average	934K	7.4%	Form 4
Mar 5	James C Hamilton Chief Medical Officer	Sold10b5-1 plan	10,000	$64.19	642K	4.0%	Form 4
Jan 5	James C Hamilton Chief Medical Officer	Sold10b5-1 plan 7 parts	40,164	$63.11 average	$2.53M	19%	Form 4
Jan 5	Patrick O'Brien COO	Sold10b5-1 plan 12 parts	49,493	$63.11 average	$3.12M	9.4%	Form 4
Jan 2	Christopher Richard Anzalone Chief Executive Officer	Sold10b5-1 plan 2 parts	13,187	$66.10 average	872K	0.3%	Form 4
Dec 29, 2025	Christopher Richard Anzalone Chief Executive Officer	Sold10b5-1 plan 2 parts	51,726	$69.13 average	$3.58M	1.3%	Form 4
Dec 26, 2025	Mauro Ferrari Director	Sold10b5-1 plan	7,530	$70.00	527K	9.8%	Form 4
Dec 19, 2025 – Dec 22, 2025	Christopher Richard Anzalone Chief Executive Officer	Sold10b5-1 plan 5 parts	26,031	$68.04 average	$1.77M	0.7%	Form 4
Dec 19, 2025	Victoria Vakiener Director	Sold10b5-1 plan 3 parts	10,040	$67.68 average	679K	22%	Form 4
Dec 19, 2025	William D. Waddill Director	Sold10b5-1 plan 3 parts	8,367	$67.65 average	566K	13%	Form 4
Dec 19, 2025	Adeoye Y Olukotun Director	Sold10b5-1 plan 3 parts	10,000	$67.66 average	677K	23%	Form 4
Dec 17, 2025	Christopher Richard Anzalone Chief Executive Officer	SoldNo plan 4 parts	85,000	$64.04 average	$5.44M	2.2%	Form 4
Dec 15, 2025 – Dec 16, 2025	Christopher Richard Anzalone Chief Executive Officer	SoldNo plan 12 parts	184,298	$67.00 average	$12.3M	4.5%	Form 4
Dec 5, 2025	Michael S Perry Director	SoldNo plan	16,250	$61.03	992K	12%	Form 4
Nov 28, 2025	Mauro Ferrari Director	SoldNo plan	8,750	$56.39	493K	11%	Form 4
Oct 1, 2025	James C Hamilton Chief Medical Officer	Sold10b5-1 plan	20,000	$35.00	700K	8.6%	Form 4
Sep 12, 2025	James C Hamilton Chief Medical Officer	Sold10b5-1 plan	15,000	$30.00	450K	6.1%	Form 4
Sep 2, 2025	James C Hamilton Chief Medical Officer	Sold10b5-1 plan	15,000	$25.00	375K	5.7%	Form 4
Aug 13, 2025 – Aug 15, 2025	James C Hamilton Chief Medical Officer	Sold10b5-1 plan 2 parts	10,000	$20.00 average	200K	3.7%	Form 4
Apr 9, 2025 – Apr 11, 2025	Christopher Richard Anzalone Chief Executive Officer	SoldNo plan 5 parts	141,122	$10.87 average	$1.53M	3.5%	Form 4
Mar 13, 2025	Christopher Richard Anzalone Chief Executive Officer	SoldNo plan	51,425	$15.07	775K	1.3%	Form 4
Mar 3, 2025 – Mar 4, 2025	Christopher Richard Anzalone Chief Executive Officer	Sold10b5-1 plan 2 parts	300,000	$17.58 average	$5.27M	7.4%	Form 4
Jan 23, 2025	Adeoye Y Olukotun Director	Sold10b5-1 plan	959	$21.00	20K	2.6%	Form 4
Jan 6, 2025 – Jan 7, 2025	Patrick O'Brien COO and General Counsel	Sold10b5-1 plan 3 parts	37,184	$19.80 average	736K	6.6%	Form 4
Jan 6, 2025 – Jan 7, 2025	Kenneth Allen Myszkowski Chief Financial Officer	Sold10b5-1 plan 4 parts	45,167	$19.77 average	893K	9.0%	Form 4
Jan 6, 2025	James C Hamilton Chief Discovery/Trans Medicine	Sold10b5-1 plan 2 parts	32,729	$19.82 average	649K	11%	Form 4
Jan 2, 2025	Christopher Richard Anzalone Chief Executive Officer	Sold10b5-1 plan	11,520	$19.05	219K	0.3%	Form 4
Dec 27, 2024	Adeoye Y Olukotun Director	Sold10b5-1 plan	2,850	$20.00	57K	7.2%	Form 4
Dec 23, 2024	Christopher Richard Anzalone Chief Executive Officer	Sold10b5-1 plan	12,563	$19.59	246K	0.3%	Form 4
Dec 18, 2024	Christopher Richard Anzalone Chief Executive Officer	Sold10b5-1 plan 3 parts	26,712	$21.24 average	567K	0.7%	Form 4
Dec 16, 2024 – Dec 17, 2024	William D. Waddill Director	Sold10b5-1 plan 2 parts	7,495	$21.97 average	165K	16%	Form 4
Dec 16, 2024 – Dec 17, 2024	Douglas B Given Director	Sold10b5-1 plan 2 parts	5,547	$21.91 average	122K	4.3%	Form 4
Dec 16, 2024	Victoria Vakiener Director	Sold10b5-1 plan	8,994	$21.91	197K	30%	Form 4

Aug 18No plan
Michael S Perry
Director · sold 11,600 at $87.30
$1.01M
9.4% of stake
Aug 18No plan
Adeoye Y Olukotun
Director · sold 2,000 at $86.96
174K
6.0% of stake
May 1210b5-1 plan
Hongbo Lu
Director · sold 2,970 at $76.88
228K
5.4% of stake
Apr 2310b5-1 plan
James C Hamilton
Chief Medical Officer · sold 10,000 at $75.00
750K
4.2% of stake
Apr 2210b5-1 plan
Daniel Joseph Apel
Chief Financial Officer · sold 13,095 at avg $71.35
934K
7.4% of stake
Mar 510b5-1 plan
James C Hamilton
Chief Medical Officer · sold 10,000 at $64.19
642K
4.0% of stake
Jan 510b5-1 plan
James C Hamilton
Chief Medical Officer · sold 40,164 at avg $63.11
$2.53M
19% of stake
Jan 510b5-1 plan
Patrick O'Brien
COO · sold 49,493 at avg $63.11
$3.12M
9.4% of stake
Jan 210b5-1 plan
Christopher Richard Anzalone
Chief Executive Officer · sold 13,187 at avg $66.10
872K
0.3% of stake
Dec 29, 202510b5-1 plan
Christopher Richard Anzalone
Chief Executive Officer · sold 51,726 at avg $69.13
$3.58M
1.3% of stake
Dec 26, 202510b5-1 plan
Mauro Ferrari
Director · sold 7,530 at $70.00
527K
9.8% of stake
Dec 19, 2025 – Dec 22, 202510b5-1 plan
Christopher Richard Anzalone
Chief Executive Officer · sold 26,031 at avg $68.04
$1.77M
0.7% of stake
Dec 19, 202510b5-1 plan
Victoria Vakiener
Director · sold 10,040 at avg $67.68
679K
22% of stake
Dec 19, 202510b5-1 plan
William D. Waddill
Director · sold 8,367 at avg $67.65
566K
13% of stake
Dec 19, 202510b5-1 plan
Adeoye Y Olukotun
Director · sold 10,000 at avg $67.66
677K
23% of stake
Dec 17, 2025No plan
Christopher Richard Anzalone
Chief Executive Officer · sold 85,000 at avg $64.04
$5.44M
2.2% of stake
Dec 15, 2025 – Dec 16, 2025No plan
Christopher Richard Anzalone
Chief Executive Officer · sold 184,298 at avg $67.00
$12.3M
4.5% of stake
Dec 5, 2025No plan
Michael S Perry
Director · sold 16,250 at $61.03
992K
12% of stake
Nov 28, 2025No plan
Mauro Ferrari
Director · sold 8,750 at $56.39
493K
11% of stake
Oct 1, 202510b5-1 plan
James C Hamilton
Chief Medical Officer · sold 20,000 at $35.00
700K
8.6% of stake
Sep 12, 202510b5-1 plan
James C Hamilton
Chief Medical Officer · sold 15,000 at $30.00
450K
6.1% of stake
Sep 2, 202510b5-1 plan
James C Hamilton
Chief Medical Officer · sold 15,000 at $25.00
375K
5.7% of stake
Aug 13, 2025 – Aug 15, 202510b5-1 plan
James C Hamilton
Chief Medical Officer · sold 10,000 at avg $20.00
200K
3.7% of stake
Apr 9, 2025 – Apr 11, 2025No plan
Christopher Richard Anzalone
Chief Executive Officer · sold 141,122 at avg $10.87
$1.53M
3.5% of stake
Mar 13, 2025No plan
Christopher Richard Anzalone
Chief Executive Officer · sold 51,425 at $15.07
775K
1.3% of stake
Mar 3, 2025 – Mar 4, 202510b5-1 plan
Christopher Richard Anzalone
Chief Executive Officer · sold 300,000 at avg $17.58
$5.27M
7.4% of stake
Jan 23, 202510b5-1 plan
Adeoye Y Olukotun
Director · sold 959 at $21.00
20K
2.6% of stake
Jan 6, 2025 – Jan 7, 202510b5-1 plan
Patrick O'Brien
COO and General Counsel · sold 37,184 at avg $19.80
736K
6.6% of stake
Jan 6, 2025 – Jan 7, 202510b5-1 plan
Kenneth Allen Myszkowski
Chief Financial Officer · sold 45,167 at avg $19.77
893K
9.0% of stake
Jan 6, 202510b5-1 plan
James C Hamilton
Chief Discovery/Trans Medicine · sold 32,729 at avg $19.82
649K
11% of stake
Jan 2, 202510b5-1 plan
Christopher Richard Anzalone
Chief Executive Officer · sold 11,520 at $19.05
219K
0.3% of stake
Dec 27, 202410b5-1 plan
Adeoye Y Olukotun
Director · sold 2,850 at $20.00
57K
7.2% of stake
Dec 23, 202410b5-1 plan
Christopher Richard Anzalone
Chief Executive Officer · sold 12,563 at $19.59
246K
0.3% of stake
Dec 18, 202410b5-1 plan
Christopher Richard Anzalone
Chief Executive Officer · sold 26,712 at avg $21.24
567K
0.7% of stake
Dec 16, 2024 – Dec 17, 202410b5-1 plan
William D. Waddill
Director · sold 7,495 at avg $21.97
165K
16% of stake
Dec 16, 2024 – Dec 17, 202410b5-1 plan
Douglas B Given
Director · sold 5,547 at avg $21.91
122K
4.3% of stake
Dec 16, 202410b5-1 plan
Victoria Vakiener
Director · sold 8,994 at $21.91
197K
30% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch ARWR, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with ARWR

CompareIntrinsic value

RAREUltragenyx Pharmaceutical Inc.

$17.16+3.19%40

EBSEmergent BioSolutions Inc.

$5.90-5.60%37

TGTXTG Therapeutics, Inc.

$61.63+1.45%57

FOLDAmicus Therapeutics, Inc.

No recent price45

AXSMAxsome Therapeutics, Inc.

$137.00-1.87%10

AMPHAmphastar Pharmaceuticals Inc.

$28.02+3.32%60

PCRXPacira BioSciences Inc.

$36.40+0.03%58

CPRXCatalyst Pharmaceuticals Inc.

No recent price73

Held by ETFs

ARWR is in 130 US ETFs. The largest of them, with ARWR's weight in each:

Spot a number that looks wrong? Check it in ARWR's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing ARWR

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.